- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00237666
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Bipolar II disorder is largely unstudied, with much less known about its treatment in comparison to Bipolar I disorder. While established mood stabilizers treat and prevent subsequent episodes of hypomania, chronic or recurrent depressions are harder to treat or prevent. In general the treatment of depression in Bipolar II patients is often complicated and there is no clinical unanimity on what approaches to follow. Administration of proven antidepressants would seem most appropriate and are most often used, but their use often involves a number of difficulties. Among these are:
- antidepressant efficacy is established for unipolar patients and extrapolation to Bipolar II patients is done without empirical support
- Bipolar II patients can have switches into hypomanic behavior in response to antidepressant treatment given as monotherapy
- even when mood stabilizers are concomitantly given, switches to hypomanic states still occur when antidepressants are added
- antidepressants can cause cycle acceleration or induce rapid cycling when given to Bipolar II patients
- non-response and loss of response are common reactions to antidepressants in Bipolar II patients
This study will also assess the tolerability of Geodon in the treatment of patients diagnosed with Bipolar II disorder who currently meet criteria for a Major Depressive Episode by examining the incidence of adverse events and the withdrawal rate due to adverse events.
This will be an open-label study. Subjects will be treated for 8 weeks with Geodon, starting at a dose of 20 mg twice per day. The maximum dose will be 60 mg twice per day. Subjects will have a physical exam, electrocardiogram (ECG), standard laboratory tests and a urine drug screen at the screen visit.
Efficacy evaluations will include 17-item Hamilton Depression Scale, Hamilton Anxiety Scale (HAM-D), Montgomery-Asberg Depression Rating Scale, and the Young Mania Rating Scale. Social outcome will be measured with a quality-of-life scale (the Q-LES-Q). Overall efficacy will be rated using the Clinical Global Severity and Improvement Scales.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10024
- Medical Research Network, L.L.C.
-
-
Texas
-
Plano, Texas, Förenta staterna, 75024
- The Mech Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- patients will meet DSM-IV criteria for Bipolar II Disorder, with at least one hypomanic episode as documented in the medical history or provided by an informant, or have evidence of a clear diagnosis of hypomania
- patients will currently be experiencing a major depressive episode of 2 or more weeks, but less than 12 months duration
- minimum score of 18 on the 17-item HAM-D at screen and baseline
Exclusion Criteria:
- patients will not meet criteria for Bipolar I or Schizoaffective Disorder or Schizophrenia
- patients may have co-morbid anxiety or other Axis I disorders as long as depression dominates the clinical picture
- Suicidal ideation or history that makes participation in a clinical trial unduly risky
- unstable medical conditions or any abnormality in thyroid function
- patients with a QTc of 450msec or greater on the initial ECG
- patients requiring concomitant psychotropic drugs will not be eligible, although patients on such drugs who can undergo washout will be eligible. such patients must have discontinued psychoactive drugs at least 2 weeks before beginning study, with 4 weeks for fluoxetine and depot neuroleptics
- the use of Zolpidem 5-10 mg as needed will be permitted for patients suffering from insomnia, but cannot be taken the night before a scheduled assessment
- patients with dementia or substance abuse in the last 6 months
- pregnant or lactating women will be excluded, as will those not using adequate forms of contraception
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Ziprasidone
Ziprasidone monotherapy, 20-60 mg BID.
|
Ziprasidone 20-60 mg BID, taken orally.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The Primary Efficacy Endpoint is the Comparison of Baseline and Week 8 Endpoint in the 17-item HAM-D Total Scores
Tidsram: Week 8
|
Hamilton Depression Rating Scale, measuring depression symptoms; possible total scores ranging from 0-54, with higher scores indicating greater severity of symptoms.
|
Week 8
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Mean Change From Baseline in the Hamilton Anxiety Scale (HAM-A)
Tidsram: Week 8
|
Hamilton Anxiety Rating Scale, measuring anxiety symptoms; possible total scores ranging from 0-30, with higher scores indicating greater severity of anxiety.
|
Week 8
|
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale
Tidsram: Week 8
|
Montgomery-Åsberg Depression Rating Scale, measuring depression symptoms; possible total scores ranging from 0-60, with higher scores indicating greater severity of depression.
|
Week 8
|
Percentage of Subjects With Clinical Global Inventory (CGI) Global Improvement Score of 1 or 2
Tidsram: Week 8
|
Clinical Global Impression of Improvement scale: one item, measuring overall improvement of illness; possible scores range from 1-7, with lower scores representing greater improvement. 18 subjects (60%) were responders (defined as having a CGI-I scores of 1 or 2 at Week 8/study endpoint) by the end of the trial. |
Week 8
|
Mean Change From Baseline in the CGI-Severity of Illness (CGI-S) Score at Study Endpoint
Tidsram: Week 8
|
Clinical Global Impression of Severity scale: one item, measuring overall severity of illness; possible scores range from 1-7, with higher scores representing greater severity of illness.
|
Week 8
|
Mean Change From Baseline in the Total Score of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
Tidsram: Week 8
|
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) scale consists of 14 items; possible scores range from 14-70 with higher scores indicating greater quality of life and satisfaction.
|
Week 8
|
Mean Change From Baseline in the Total Score of the Beck Depression Inventory (BDI)
Tidsram: Week 8
|
Beck Depression Inventory, self-rated scale measuring depression symptoms; possible total scores ranging from 0-63, with higher scores indicating greater severity of depression.
|
Week 8
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Michael R Liebowitz, MD, Medical Research Network, L.L.C.
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Beteendesymtom
- Mentala störningar
- Humörstörningar
- Depressiv sjukdom
- Depression
- Depressiv sjukdom, major
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Depressiva medel i centrala nervsystemet
- Antipsykotiska medel
- Lugnande medel
- Psykotropa droger
- Serotoninmedel
- Dopaminmedel
- Serotoninantagonister
- Dopaminantagonister
- Ziprasidon
Andra studie-ID-nummer
- 04-3945-A 01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Major Depressive Episod
-
University of WarsawHar inte rekryterat ännuMåttlig depressiv episod | Mild depressiv episod
-
Jiangsu Province Nanjing Brain HospitalRekryteringMajor Depressive EpisodKina
-
Jiangsu Province Nanjing Brain HospitalRekrytering
-
TakedaAvslutadAkut depressiv episodFörenta staterna, Argentina, Chile, Colombia, Mexiko
-
Assistance Publique - Hôpitaux de ParisRekryteringMajor Depressive EpisodFrankrike
-
Centre Hospitalier Universitaire de NīmesRekryteringSjälvmordstankar | Major Depressive EpisodFrankrike
-
Stanford UniversityRekryteringBehandling Resistent depression | Bipolär II sjukdom, senaste episod Major depressiv | Aktuell depressiv episodFörenta staterna
-
Mental Health Services in the Capital Region, DenmarkInnovation Fund DenmarkRekryteringMåttlig depression | Återkommande depressiv sjukdom, aktuell episod måttlig | Svår depressiv episod utan psykotiska symtom | Återkommande depressiv sjukdom, aktuell episod allvarlig utan psykotiska symtomDanmark
-
University Hospital, ToursRekrytering
-
The Royal Ottawa Mental Health CentreHar inte rekryterat ännuDepression | Depressiv sjukdom, major | Depressiv episodKanada
Kliniska prövningar på Ziprasidone
-
Donald C. Goff, MDPfizerAvslutadSchizofreniFörenta staterna
-
Bronx Psychiatric CenterPfizer; Buffalo Psychiatric Center; Rochester Psychiatric CenterAvslutadSchizofreni | Schizoaffektiv sjukdomFörenta staterna
-
Fundació Institut de Recerca de l'Hospital de la...Pfizer; Ministry of Health, Spain; REM-TAP NetworkAvslutadBorderline personlighetsstörningSpanien
-
Pfizer's Upjohn has merged with Mylan to form Viatris...AvslutadPsykotiska störningar | SchizofreniKalkon, Egypten, Grekland, Libanon, Jordanien, Kuwait, Saudiarabien, Sydafrika, Förenade arabemiraten
-
Yale UniversityAvslutad
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Avslutad
-
Pfizer's Upjohn has merged with Mylan to form Viatris...AvslutadBipolär sjukdomFörenta staterna
-
Dr. Reddy's Laboratories LimitedAvslutad
-
Tufts Medical CenterPfizerAvslutadDepression | Bipolär sjukdom | Bipolär depressionFörenta staterna
-
Tufts Medical CenterDuke University; University of South CarolinaAvslutadDepression | Bipolär sjukdom